X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The collaboration aims to develop new bispecific antibody-drug conjugates (bsADCs) using Biocytogen’s RenLite® mice platform that can produce fully human antibodies with diverse epitopes and high affinity.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: ABL Bio
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration March 25, 2024
Details:
Through the collaboration, Gilead will be given access to Biocytogen’s extensive fully human antibody library generated against a wide range of therapeutic targets.
Lead Product(s): Undisclosed
Therapeutic Area: Technology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Partner/Sponsor/Collaborator: Gilead Sciences
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration February 19, 2024
Details:
The agreement grants Radiance an option to license from Biocytogen a first-in-class fully human anti-HER2/TROP2 bispecific antibody-drug conjugate, YH012, for therapeutic product development, manufacturing and commercialization for all human indications worldwide.
Lead Product(s): YH012
Therapeutic Area: Oncology Product Name: YH012
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Radiance Biopharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement January 08, 2024
Details:
Biocytogen pharmaceuticals is developing a WT1/CD3/4-1BB inhibitor antibody drug candidate, which is currently being evaluated for the treatment of hematological malignancies.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: CtM Biotech
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 27, 2023
Details:
The agreement grants Neurocrine Biosciences access to Biocytogen’s fully human antibodies against multiple specified targets, with an option to license selected antibodies for therapeutic product development, manufacturing and commercialization for all uses worldwide.
Lead Product(s): Undisclosed
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Large molecule
Partner/Sponsor/Collaborator: Neurocrine Biosciences
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement December 19, 2023
Details:
Biocytogen will grant Ona access to evaluate Biocytogen’s proprietary RenMice®-derived fully human antibodies against a specific tumor target, with an option to exclusively license selected antibodies for ADC development, manufacturing and commercialization.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Large molecule
Partner/Sponsor/Collaborator: Ona Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement December 18, 2023
Details:
Under the terms of the agreement, Myricx will develop and commercialize ADCs based on an antibody developed using Biocytogen’s proprietary RenMice® platform and will expand Myricx’s ADC pipeline of proprietary monoclonal antibodies (mAbs) against important cancer targets.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Large molecule
Partner/Sponsor/Collaborator: Myricx Bio
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement September 07, 2023
Details:
Under the terms of the agreement, Pheon will develop and commercialize a next generation antibody-drug conjugate (ADC) for a wide range of hard-to-treat cancers developed using Biocytogen’s proprietary RenMiceTM platforms.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Large molecule
Partner/Sponsor/Collaborator: Pheon Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement July 05, 2023
Details:
Janssen will use Biocytogen’s proprietary RenLite® platform to discover, research, develop, manufacture and commercialize fully human antibody therapeutics with a common light chain and other biological therapeutics for an unlimited number of drug targets and indications.
Lead Product(s): Antibody
Therapeutic Area: Technology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Partner/Sponsor/Collaborator: Johnson & Johnson Innovative Medicine
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement March 08, 2023
Details:
Biocytogen has launched the “Nano 100 Project” which aims to develop fully human therapeutic nanobodies against over 100 targets, including tumor associated antigens (TAAs), GPCRs, immune-checkpoints, cytokines, and factors related to neurological diseases.
Lead Product(s): Undisclosed,Nanobody Therapeutic
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 20, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
